2025 Volume 14 Issue 2
Creative Commons License

The Biological Identity Ledger for Tracing Protein Corona Formation, Immune Recognition, Tissue Distribution, and Nanocarrier Fate


, ,
  1. Department of Nanocarrier Biological Identity and Protein Corona, Faculty of Pharmacy, University of Oslo, Oslo, Norway.
  2. Department of Immune Recognition and Tissue Distribution, Faculty of Pharmacy, University of Bergen, Bergen, Norway.
Abstract

Nanocarriers are commonly defined by properties measured before administration, yet their biologically operative identity changes as they encounter proteins, lipids, antibodies, cells, extracellular matrices, and intracellular environments. Fragmented reporting of manufactured attributes, acquired coronas, recognition events, tissue exposure, degradation, and clearance prevents these transformations from being traced as one evidence chain. This Original Evidence Architecture Article proposes the Biological Identity Ledger, a non-empirical scientific traceability architecture that links batch-resolved synthetic identity and manufacturing provenance to biological exposure events, acquired corona states, immune-recognition states, and fate states. Its central principle is that nanocarrier identity is neither a single static descriptor nor equivalent to efficacy: it is a versioned, compartment- and time-indexed record whose interpretation depends on measurement method, biological context, and uncertainty. The architecture introduces eight linked constructs: the Synthetic Identity Record, Manufacturing Provenance Record, Biological Exposure Event, Acquired Corona State, Recognition State, Fate State, Temporal-Compartment Key, and Evidence Provenance and Uncertainty Layer. Temporal updating is used to represent corona exchange, barrier transitions, intracellular remodeling, payload release, degradation, and clearance without presuming a universal causal sequence. Evidence provenance separates observation from inference and records analytical recovery limits, biological variability, and transferability constraints. Validation would require schema testing, longitudinal and multi-compartment experiments, batch-linked manufacturing studies, human-matrix and species-aware comparisons, interlaboratory reproducibility, and prospective assessment before decision use. The proposed ledger is an original conceptual synthesis for organizing testable relationships and reporting requirements; it is not a validated predictive model, clinical recommendation, regulatory standard, or deployment-ready system.


How to cite this article
Vancouver
Eriksen K, Berg S, Dahl M. The Biological Identity Ledger for Tracing Protein Corona Formation, Immune Recognition, Tissue Distribution, and Nanocarrier Fate. Int J Pharm Res Allied Sci. 2025;14(2):35-44. https://doi.org/10.51847/QvyuCebgyC
APA
Eriksen, K., Berg, S., & Dahl, M. (2025). The Biological Identity Ledger for Tracing Protein Corona Formation, Immune Recognition, Tissue Distribution, and Nanocarrier Fate. International Journal of Pharmaceutical Research and Allied Sciences, 14(2), 35-44. https://doi.org/10.51847/QvyuCebgyC
Related articles:
Most viewed articles:
Issue 3 Volume 14 (2025)